Sugi Predict

Sugi Predict / Compounds / SCHEMBL19995400

SCHEMBL19995400

SCHEMBL19995400

N#Cc1ccc(Br)c(C(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.38
▸ TTR P02766 1/20 0.38
▸ ALB P02768 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PNMT P11086 1/20 0.35
▸ PTPN1 P18031 2/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ PDE3B Q13370 1/20 0.34
▸ PDE3A Q14432 1/20 0.34
▸ CXCR1 P25024 1/20 0.33
▸ CXCR2 P25025 1/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ CYP2A6 P11509 2/20 0.32
▸ IMPDH2 P12268 1/20 0.32
▸ IMPDH1 P20839 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ CA12 O43570 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9931300 0.84 MEN1 (0.42) MEN1TTRALBKMT2APNMT
SCHEMBL1921906 0.82 MEN1 (0.39) MEN1TTRALBKMT2APTPN1
SCHEMBL29865178 0.82 MEN1 (0.39) MEN1TTRALBKMT2APTPN1
SCHEMBL4419556 0.80 PTPN1 (0.49) MEN1TTRALBKMT2APNMT
SCHEMBL1798845 0.79 GRIN2B (0.39) PNMTCYP2A6IMPDH2IMPDH1ALDH1A1
SCHEMBL30876218 0.79 GRIN2B (0.39) PNMTCYP2A6IMPDH2IMPDH1ALDH1A1
SCHEMBL27469967 0.78 MEN1 (0.36) MEN1TTRALBKMT2APTPN1
SCHEMBL16961692 0.77 MEN1 (0.35) MEN1TTRALBKMT2APTPN1
SCHEMBL20482938 0.77 MEN1 (0.39) MEN1TTRALBKMT2APTPN1
SCHEMBL16954337 0.77 MEN1 (0.32) MEN1TTRALBKMT2APNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743462-A1 COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS Tay Therapeutics Limited (GB) 2026-05-20 — — EP disclosed
WO-2025012643-A1 COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS Tay Therapeutics Limited (GB) 2025-01-16 — — WO disclosed
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 — — EP disclosed
CN-116635028-A Modulators of c-MYC mRNA translation and their use in the treatment of cancer 艾尼莫生物科技公司 2023-08-22 — — CN disclosed
WO-2023072197-A1 PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF HANSOH BIO LLC (US) 2023-05-04 — — WO disclosed
CN-109952289-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-12-09 — — CN disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 — — US disclosed
CN-109790116-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-10-28 — — CN disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 — — WO disclosed
US-20200261411-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-08-20 — — US disclosed
US-10588891-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-03-17 — — US disclosed
EP-3515887-A1 TRPV4 ANTAGONISTS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
EP-3515888-A1 TRPV4 ANTAGONISTS GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
CN-109952289-A TRPV4 antagonist 葛兰素史密斯克莱知识产权（第2 号）有限公司 2019-06-28 — — CN disclosed
CN-109790116-A TRPV4 antagonist 葛兰素史密斯克莱知识产权（第2 号）有限公司 2019-05-21 — — CN disclosed
WO-2018055524-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055526-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MEN1 1720/4885TTR 3266/4885ALB 3961/4885
US-10588891-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 MEN1 4667/4885TTR 4203/4885ALB 4627/4885
US-20200261411-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 MEN1 4667/4885TTR 4203/4885ALB 4627/4885
US-20190216774-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 MEN1 4667/4885TTR 4203/4885ALB 4627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.